Short-Term Treatment with Sevelamer Increases Serum Fetuin-A Concentration and Improves Endothelial Dysfunction in Chronic Kidney Disease Stage 4 Patients | Zendy

Kayser Çağlar | Zendy; Mahmut İlker Yılmaz | Zendy; Mutlu Sağlam | Zendy; Erdinç Çakır | Zendy; Cengizhan Açıkel | Zendy; Tayfun Eyıleten | Zendy; Müjdat Yenicesu | Zendy; Yusuf Oğuz | Zendy; Abdülgaffar Vural | Zendy; Juan Jesús Carrero | Zendy; Jonas Axelsson | Zendy; Bengt Lindholm | Zendy; Peter Stenvinkel | Zendy

Open Access

Short-Term Treatment with Sevelamer Increases Serum Fetuin-A Concentration and Improves Endothelial Dysfunction in Chronic Kidney Disease Stage 4 Patients

Author(s) -

Kayser Çağlar,

Mahmut İlker Yılmaz,

Mutlu Sağlam,

Erdinç Çakır,

Cengizhan Açıkel,

Tayfun Eyıleten,

Müjdat Yenicesu,

Yusuf Oğuz,

Abdülgaffar Vural,

Juan Jesús Carrero,

Jonas Axelsson,

Bengt Lindholm,

Peter Stenvinkel

Publication year - 2007

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.02810707

Subject(s) - sevelamer , medicine , kidney disease , endocrinology , endothelial dysfunction , calcification , gastroenterology , prospective cohort study , urology , hyperphosphatemia

Vascular calcification and endothelial dysfunction contribute to the development of cardiovascular disease in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium-based phosphate binder, has been shown to attenuate cardiovascular calcification in CKD patients, although the exact mechanism has not been clarified. This study was designed to investigate the effect of short-term sevelamer treatment on both serum fetuin-A concentrations and endothelial dysfunction seen in CKD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research